The 29th Annual Research Conference will be a hybrid event used to assemble Investigators and Researchers from TRIO-US and UCLA, along with individuals from the Pharmaceutical Industry. UCLA Principal Investigators will present areas of advancement in their respective oncology disease sites followed by a question-and-answer session for more in-depth conversation. We will also host four product theater discussions from our Platinum and Gold Sponsors.
The Research Conference will have a national impact on oncologists, internal medicine physicians, oncology nurses, clinical research professionals, and many more from across the United States. The Research Conference has been successful in boosting the accrual of numerous historical clinical trials, while educating attendees on the current state of multiple diseases and ongoing research.
As stated above the conference will be a hybrid event as we have found people appreciate the option to attend in-person and virtually. We are pleased to announce that we can host 200 attendees for the in-person option and an additional 1000 virtually.
ATTENDANCE OPTIONS
IN-PERSON ATTENDANCE –As the popularity of this conference continues to grow we will be drawing 200 names to determine who can attend in-person. The cost to attend in-person is $1,000, those attending from TRIO-US & UCLA will receive a discount code for this registration fee. It is our hope that closer to the event we may be able to add to the number of in-person attendees.
VIRTUAL ATTENDANCE – As we are using vFairs to help host our hybrid event we can have up to 1000 virtual attendees. This allows for a broader reach of who can attend our conference as we are normally capped at 200 in-person attendees. The cost to attend the full conference virtually is $500 or you may choose to select a grouping of sessions for $200, those attending from TRIO-US & UCLA will receive a discount code for registration.
Translational Research In Oncology-US, Inc. (TRIO-US) is a clinical oncology research organization devoted to evaluating novel agents for the treatment of cancer. It is affiliated with the Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA). The primary purpose of the TRIO-US Network is to offer important and select cutting-edge therapeutic trials to participants outside of UCLA’s catchment area. TRIO-US manages and administers the conduct of clinical research trials for its network of 15 centers across the United States and conducts two types of trials: industry-sponsored and TRIO-US's own investigator-initiated trials. This network provides UCLA with access to a wider potential patient pool needed to conduct proof-of-concept and early phase clinical trials. For more information about TRIO-US please visit our website: www.trio-us.org . For more information about UCLA JCCC please visit our website: https://cancer.ucla.edu
The agenda is forthcoming
November 1, 2024 18:45
John Glaspy, MD
